Metacrine to Participate in Upcoming Investor Conferences
November 23 2020 - 6:30AM
Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical
company focused on discovering and developing differentiated
therapies for patients with liver and gastrointestinal diseases,
today announced that Preston Klassen, M.D., MHS, president and
chief executive officer of Metacrine, will present at the following
December investor conferences:
- Piper Sandler 32nd Annual Virtual
Healthcare Conference (fireside chat) being held December 1-3,
2020. Company presentations will be available for registered
attendees on the Piper Sandler conference site from November 23 to
December 3. Metacrine will participate in 1x1 meetings with
investors during the conference on Wednesday, December 2,
2020.
- Evercore ISI 3rd Annual HealthCONx
(fireside chat) on Thursday, December 3, 2020 at 3:55 p.m. ET/12:55
p.m. PT. Metacrine will participate in 1x1 meetings with investors
during the conference on Thursday, December 3, 2020.
Webcasts of the presentations will be available in the investor
section of the company's website at www.metacrine.com. The webcasts
will be archived for 60 days following the presentations.
About MetacrineMetacrine, Inc.
(Nasdaq: MTCR) is a clinical-stage biopharmaceutical company
building a differentiated pipeline of therapies to treat liver and
gastrointestinal (GI) diseases. The company’s most advanced
programs, MET409 and MET642, target the farnesoid X receptor (FXR),
which is central to modulating liver and GI diseases. Both MET409
and MET642 are currently being investigated in clinical trials as
potential new treatments for non-alcoholic steatohepatitis
(NASH).
Contact:Chelcie ListerTHRUST Strategic
Communications910.777.3049investors@metacrine.com
Metacrine (NASDAQ:MTCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Metacrine (NASDAQ:MTCR)
Historical Stock Chart
From Apr 2023 to Apr 2024